These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34158378)

  • 1. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
    Besse L; Besse A; Stolze SC; Sobh A; Zaal EA; van der Ham AJ; Ruiz M; Phuyal S; Büchler L; Sathianathan M; Florea BI; Borén J; Ståhlman M; Huber J; Bolomsky A; Ludwig H; Hannich JT; Loguinov A; Everts B; Berkers CR; Pilon M; Farhan H; Vulpe CD; Overkleeft HS; Driessen C
    Cancer Res; 2021 Sep; 81(17):4581-4593. PubMed ID: 34158378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
    Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
    Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
    Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
    Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Besse A; Sedlarikova L; Buechler L; Kraus M; Yang CH; Strakova N; Soucek K; Navratil J; Svoboda M; Welm AL; Joerger M; Driessen C; Besse L
    Br J Cancer; 2024 Sep; 131(5):918-930. PubMed ID: 38969867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
    Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
    Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
    Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
    Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
    Pyrko P; Kardosh A; Wang W; Xiong W; Schönthal AH; Chen TC
    Cancer Res; 2007 Nov; 67(22):10920-8. PubMed ID: 18006837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
    Brüning A; Burger P; Vogel M; Rahmeh M; Gingelmaiers A; Friese K; Lenhard M; Burges A
    Cancer Biol Ther; 2009 Feb; 8(3):226-32. PubMed ID: 19106637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets.
    Kopecka J; Trouillas P; Gašparović AČ; Gazzano E; Assaraf YG; Riganti C
    Drug Resist Updat; 2020 Mar; 49():100670. PubMed ID: 31846838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
    Allegra A; Innao V; Allegra AG; Pulvirenti N; Pugliese M; Musolino C
    Oncol Rep; 2020 Jun; 43(6):1729-1736. PubMed ID: 32236596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
    Gupta AK; Li B; Cerniglia GJ; Ahmed MS; Hahn SM; Maity A
    Neoplasia; 2007 Apr; 9(4):271-8. PubMed ID: 17460771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
    Kachko I; Maissel A; Mazor L; Ben-Romano R; Watson RT; Hou JC; Pessin JE; Bashan N; Rudich A
    Endocrinology; 2009 Jun; 150(6):2618-26. PubMed ID: 19179444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Bruning A; Vogel M; Mylonas I; Friese K; Burges A
    Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
    Okubo K; Isono M; Asano T; Sato A
    Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.